In this episode of TOGA's 'Conversations in Lung Cancer Research,' A/Prof Mel Moore interviews A/Prof Surein Arulananda, the interim Director of Medical Oncology and Thoracic Oncology Trials Lead at Monash Health and Convenor at the 2026 TOGA ASM. They discuss his academic background, his unexpected journey into oncology, a fellowship in Boston and MBA in London and his vision for the future of lung cancer treatment. [0:00] Introduction [2:05] Career Foundations [3:19] Choosing Oncology [6:39] Translational PhD [12:00] Finding the Balance [13:36] The Boston Fellowship [18:00] The MBA Journey in London [25:35] Targeted Therapies + SCLC [30:10] Convening the TOGA ASM [32:53] Future Ambitions Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related